Larimar Therapeutics, Inc. LRMR · Stock Open Larimar Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Larimar Therapeutics, Inc. Analysis (LRMR)
Is Larimar Therapeutics, Inc. a good investment? Larimar Therapeutics, Inc. (LRMR) is currently trading at 2.68 USD. Market analysts have a consensus price target of 14.40 USD. This suggests a potential upside from current levels.
Earnings Schedule: Larimar Therapeutics, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -1.06.
Investor FAQ
Does Larimar Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -1.99.
Company Profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| May 29, 2020 | 0.08 |
Community Discussion